What is claimed is:

1. Use of a lipid binding protein-based complex for the manufacture of a medicament for the treatment of a subject having one or more symptoms associated with leukocytosis, optionally wherein the one or more symptoms comprise a fever; bleeding or bruising; sweating; pain or tingling in the legs, arms, or abdomen; one or more vision problems; unclear thinking; loss of appetite; and/or trouble breathing (*e.g.*, shortness of breath, below normal blood oxygen levels).

2. The use of claim 1, wherein the subject has or is at risk of developing leukocytosis due to inflammation, an infection, a white blood cell disorder, physical stress, emotional stress, medication, or an allergic reaction.

3. The use of claim 1 or claim 2, wherein the subject:

(a) has an infection, optionally wherein the infection is a viral infection, optionally wherein the viral infection is a coronavirus infection, which is optionally COVID-19; a bacterial infection; a fungal infection; or a parasitic infection;

(b) has diabetes;

(c) has a white blood cell disorder; or

(d) has leukocytosis, optionally wherein the subject has a white blood cell count above 11×10^9 per L.

4. Use of a lipid binding protein-based complex for the manufacture of a medicament for the treatment of endothelial dysfunction in a subject, wherein the medicament is formulated for administration of a high dose of the lipid binding protein-based complex.

5. Use of a lipid binding protein-based complex for the manufacture of a medicament for the treatment of a subject having or at risk of developing carditis, optionally wherein the carditis is myocarditis and/or pericarditis, optionally wherein the subject has an infection, such as a viral infection.

6. The use of claim 5, wherein the subject is at risk of carditis.

7. Use of a lipid binding protein-based complex for the manufacture of a medicament for the treatment of leukocytosis.

8. The use of any one of claims 1 to 7, wherein the lipid binding protein-based complex is CER-001.

9. Use of a lipid binding protein-based complex for the manufacture of a medicament for the treatment of a subject experiencing acute coronary syndrome or stroke or who has experienced acute coronary syndrome or stroke, wherein the medicament is formulated for administration to the subject at a high dose of the lipid binding protein-based complex.

10. Use of an Apolipoprotein A-I (“ApoA-I”) formulation, comprising ApoA-I and one or more lipids, for the manufacture of a medicament for the treatment of a subject having one or more symptoms associated with leukocytosis.

11. Use of an Apolipoprotein A-I (“ApoA-I”) formulation, comprising ApoA-I and one or more lipids, for the manufacture of a medicament for the treatment of a subject having endothelial dysfunction.

12. Use of an Apolipoprotein A-I (“ApoA-I”) formulation, comprising ApoA-I and one or more lipids, for the manufacture of a medicament for the treatment of a subject having or at risk of developing carditis, .

13. Use of an Apolipoprotein A-I (“ApoA-I”) formulation comprising ApoA-I and one or more lipids, for the manufacture of a medicament for the treatment of a subject having or at risk of developing leukocytosis.

14. The use of any one of claims 10 to 13, wherein the ApoA-I has the amino acid sequence of amino acids 25-267 of SEQ ID NO:2, optionally wherein the ApoA-I is recombinantly expressed.

15. The use of any one of claims 10 to 14 wherein said one or more lipids comprise neutral lipids, optionally wherein the neutral lipids comprise sphingomyelin, optionally wherein the sphingomyelin comprises synthetic palmitoylsphingomyelin.

16. The use of any one of claims 10 to 15, wherein the one or more lipids further comprise negatively charged lipids, optionally wherein the negatively charged lipids comprise 1,2-dipalmitoyl-sn-glycero-3-[phospho-rac-(1-glycerol)] ("DPPG") or a salt thereof.

17. The use of claim 15 or claim 16, wherein said lipids consist of 95 to 99 weight % neutral phospholipid and 1 to 5 weight % negatively charged phospholipid, 96 to 98 weight % neutral phospholipid and 2 to 4 weight % negatively charged phospholipid, or 97 weight % neutral phospholipid and 3 weight % negatively charged phospholipid.

18. The use of any one of claims 10 to 17, wherein the formulation which has an ApoA-I to lipid ratio ranging from 1:2 to 1:3 by weight, optionally an ApoA-I to lipid ratio of about 1:2.7 by weight.